インフルエンザ診断市場

出版:MarketsandMarkets

Influenza Diagnostics Market by Product (Test Kits, Instruments), Test Type (Traditional (RIDT, Viral Culture, Serological), Molecular (PCR, INAAT- NASBAT, TMABAS)), End User (Diagnostic Laboratories, Hospitals, Clinics), Region-Global Forecast to 2026

出版 MarketsandMarkets
出版年月 2021年9月
ページ数 188
図表数 195
種別 英文調査報告書

レポート目次  お問合せ

インフルエンザ診断市場 製品(テストキット、機器)、テストタイプ(従来型(RIDT、ウイルス培養、血清学的)、分子(PCR、INAAT-NASBAT、TMABAS))、エンドユーザー(診断研究所、病院、クリニック)、地域別

The global influenza diagnostics market is projected to reach USD 1.1 billion by 2026 from USD 0.8billion in 2021, at a CAGR of 7.7% during the forecast period. Market growth is driven by factors such as the growth in influenza research for diagnostic technologies,rising demand for rapid disease diagnosis and increasing prevalence of influenza. On the other hand, therising healthcare costs, variabilities in test sensitivity and specificityare the major factors hampering the growth of this market.
“The test kits and reagents segment accounted for the highest growth rate in theinfluenza diagnostics market, by product, during the forecast period”
Theinfluenza diagnostics market is segmented into test kits and reagents, instruments and other productsbased on product. In 2020, the test kits and reagents segment accounted for the highest growth rate in the influenza diagnostics market. Increasing prevalence of influenza and rising demand for rapid disease diagnosis are major factor contributing to the growth of this segment.
“The molecular diagnostic tests segment accounted for the highest growth rate in the influenza diagnostics market, by test type, during the forecast period”
The influenza diagnostics market is segmented into molecular diagnostic tests and traditional diagnostic tests based on test type. In 2020, the molecular diagnostic tests segment accounted for the highest growth rate in the influenza diagnostics market. Growth in influenza research for diagnostic technologies and rising demand for rapid disease diagnosis are major factor contributing to the growth of this segment.
“Diagnostic laboratories segment accounted for the highest CAGR”
Based onend user, the influenza diagnosticsmarket is segmented intodiagnostic laboratories, hospitals and clinics and other end users. In 2020, the hospitals and clinics segment accounted for the highest CAGR. This can be attributed to therising demand for rapid disease diagnosis and increasing prevalence of influenza.
“Asia Pacific: The fastest-growing regionin influenza diagnostics market”
The global influenza diagnostics market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is projected to register the highest CAGR during the forecast period.Factors such as the rising demand for rapid disease diagnosis and growth in influenza research for diagnostic technologiesare driving the growth of the influenza diagnostics market in this region.

The primary interviews conducted for this report can be categorized as follows:

• By Company Type: Tier 1 – 40%, Tier 2 – 30%,and Tier 3 -30%
• By Designation: C-level – 27%, D-level – 18%, and Others – 55%
• By Region: North America -51%, Europe – 21%, Asia Pacific – 18%, Latin America – 6%, and the Middle East & Africa – 4%
Lists of Companies Profiled in the Report:

• Danaher Corporation (US)
• Siemens Healthineers (Germany)
• Thermo Fisher Scientific, Inc. (US)
• F. Hoffmann-LA Roche AG (Switzerland)
• Abbott Laboratories, Inc. (Us)
• Hologic, Inc. (US)
• bioMérieux SA (France)
• Quidel Corporation (US)
• Becton, Dickinson and Company (US)
• Meridian Bioscience (US)
• GenMark Diagnostics, Inc. (US)
• Luminex Corporation (US)
• Tecan Trading AG (Switzerland)
• DiaSorin SA (Italy)
• altona Diagnostics GmbH (Germany)
• SEKISUI Diagnostics (US)
• SA Scientific Ltd. (US)
• CorisBioConcept SPRL (Belgium)
• ELITech Group (France)
• Mast Group Ltd. (UK)
• Genome Diagnostics, Pvt. Ltd. (India)
• Germaine Laboratories, Inc. (US)
• Response Biomedical Corp. (Canada)
• Tauns Laboratories, Inc. (Japan)
• 3B BlackBio Biotech India Ltd. (India)
Research Coverage:
This report provides a detailed picture of the global influenza diagnostics market. It aims at estimating the size and future growth potential of the market across different segments, such as product, test type, end userand region. The report also includes an in-depth competitive analysis ofthe key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall influenza diagnostics market and its subsegments.It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.


目次

1 INTRODUCTION 28
1.1 OBJECTIVES OF THE STUDY 28
1.2 MARKET DEFINITION 28
1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY 29
1.2.2 MARKETS COVERED 30
FIGURE 1 INFLUENZA DIAGNOSTICS MARKET SEGMENTATION 30
1.2.3 YEARS CONSIDERED FOR THE STUDY 31
1.3 CURRENCY 31
1.4 LIMITATIONS 31
1.5 STAKEHOLDERS 32
1.6 SUMMARY OF CHANGES 32
2 RESEARCH METHODOLOGY 34
2.1 RESEARCH DATA 34
2.2 RESEARCH APPROACH 34
FIGURE 2 INFLUENZA DIAGNOSTICS MARKET: RESEARCH DESIGN 34
2.2.1 SECONDARY DATA 35
2.2.1.1 Key data from secondary sources 35
2.2.2 PRIMARY DATA 36
2.2.2.1 Key data from primary sources 36
2.2.2.2 Key industry insights 37
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 38
2.3 MARKET SIZE ESTIMATION 38
2.3.1 BOTTOM-UP APPROACH 39
FIGURE 4 INFLUENZA DIAGNOSTICS MARKET: BOTTOM-UP APPROACH 39
FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 39
2.3.2 TOP-DOWN APPROACH 40
FIGURE 6 INFLUENZA DIAGNOSTICS MARKET: TOP-DOWN APPROACH 40
2.4 MARKET BREAKDOWN & DATA TRIANGULATION 40
FIGURE 7 DATA TRIANGULATION METHODOLOGY 41
2.5 ASSUMPTIONS FOR THE STUDY 42
2.6 GROWTH RATE ASSUMPTIONS 42
2.7 LIMITATIONS 43
2.8 RISK ASSESSMENT 43
2.9 COVID-19 HEALTH ASSESSMENT 43
2.10 COVID-19 ECONOMIC ASSESSMENT 44

2.11 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO 44
FIGURE 8 CRITERIA IMPACTING THE GLOBAL ECONOMY 44
FIGURE 9 RECOVERY SCENARIO OF THE GLOBAL ECONOMY 45
2.12 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE INFLUENZA DIAGNOSTICS MARKET 46
3 EXECUTIVE SUMMARY 47
FIGURE 10 INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT,
2021 VS. 2026 (USD MILLION) 47
FIGURE 11 INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE,
2021 VS. 2026 (USD MILLION) 48
FIGURE 12 INFLUENZA DIAGNOSTICS MARKET, BY END USER,
2021 VS. 2026 (USD MILLION) 48
FIGURE 13 INFLUENZA DIAGNOSTICS MARKET, BY REGION,
2021 VS. 2026 (USD MILLION) 49
4 PREMIUM INSIGHTS 50
4.1 INFLUENZA DIAGNOSTICS MARKET OVERVIEW 50
FIGURE 14 INCREASING PREVALENCE OF INFLUENZA TO DRIVE MARKET GROWTH 50
4.2 INFLUENZA DIAGNOSTICS MARKET SHARE, BY PRODUCT, 2021 VS. 2026 50
FIGURE 15 TEST KITS & REAGENTS WILL CONTINUE TO DOMINATE THE MARKET IN 2026 50
4.3 INFLUENZA DIAGNOSTICS MARKET SHARE, BY TEST TYPE, 2021 VS. 2026 51
FIGURE 16 MOLECULAR DIAGNOSTIC TESTS TO DOMINATE THE MARKET DURING THE FORECAST PERIOD 51
4.4 INFLUENZA DIAGNOSTICS MARKET SHARE, BY END USER, 2021 VS. 2026 51
FIGURE 17 DIAGNOSTIC LABORATORIES ARE THE LARGEST END USERS OF THE INFLUENZA DIAGNOSTICS MARKET 51
4.5 INFLUENZA DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 52
FIGURE 18 NORTH AMERICA TO COMMAND THE LARGEST SHARE AND ASIA PACIFIC TO REGISTER THE HIGHEST GROWTH RATE IN THE INFLUENZA DIAGNOSTICS MARKET DURING THE FORECAST PERIOD 52
5 MARKET OVERVIEW 53
5.1 INTRODUCTION 53
5.2 MARKET DYNAMICS 53
FIGURE 19 INFLUENZA DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 53
5.2.1 DRIVERS 53
5.2.1.1 Increasing prevalence of influenza 53
5.2.1.2 Growth in influenza research for diagnostic technologies 54
5.2.1.3 Rising demand for rapid disease diagnosis 54
5.2.2 RESTRAINTS 55
5.2.2.1 Variabilities in test sensitivity and specificity 55
5.2.2.2 Rising healthcare costs 55
5.2.3 OPPORTUNITIES 55
5.2.3.1 Advancements in genomic and proteomic technologies 55
5.2.3.2 Significant growth prospects in developing countries 55
5.2.4 CHALLENGES 56
5.2.4.1 Lack of skilled professionals 56
5.2.4.2 Stringent regulatory frameworks 56
5.3 IMPACT OF COVID-19 ON THE INFLUENZA DIAGNOSTICS MARKET 57
5.4 PRICING ANALYSIS 58
TABLE 1 PRICES OF INFLUENZA DIAGNOSTIC PRODUCTS (2021) 58
5.5 PATENT ANALYSIS 59
5.6 TRADE ANALYSIS 59
5.6.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS 59
TABLE 2 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2016–2020 (USD MILLION) 59
TABLE 3 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS,
BY COUNTRY, 2016–2020 (USD MILLION) 60
5.7 VALUE CHAIN ANALYSIS 60
FIGURE 20 MAJOR VALUE IS ADDED DURING THE MANUFACTURING & ASSEMBLY PHASES 60
5.8 SUPPLY CHAIN ANALYSIS 61
FIGURE 21 DISTRIBUTION—A STRATEGY PREFERRED BY PROMINENT COMPANIES 62
5.9 ECOSYSTEM ANALYSIS OF THE INFLUENZA DIAGNOSTICS MARKET 62
FIGURE 22 INFLUENZA DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS 62
5.9.1 ROLE IN THE ECOSYSTEM 62
5.10 PORTER’S FIVE FORCES ANALYSIS 63
TABLE 4 INFLUENZA DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 63
5.10.1 THREAT FROM NEW ENTRANTS 64
5.10.2 THREAT FROM SUBSTITUTES 64
5.10.3 BARGAINING POWER OF BUYERS 64
5.10.4 BARGAINING POWER OF SUPPLIERS 64
5.10.5 DEGREE OF COMPETITION 64
5.11 PESTLE ANALYSIS 65
5.12 REGULATORY LANDSCAPE 66
5.12.1 NORTH AMERICA 66
5.12.1.1 US 66
5.12.1.2 Canada 66
5.12.2 EUROPE 66
5.12.3 ASIA PACIFIC 66
5.12.3.1 Japan 66
5.12.3.2 India 67
5.12.3.3 China 67
5.12.4 LATIN AMERICA 67
5.12.4.1 Brazil 67
5.12.4.2 Mexico 67
5.12.5 MIDDLE EAST 67
5.12.6 AFRICA 68
5.13 TECHNOLOGY ANALYSIS 68
5.14 DISRUPTIVE TECHNOLOGIES IN THE INFLUENZA DIAGNOSTICS MARKET 69
5.14.1 REVENUE SHIFT & REVENUE POCKETS FOR THE INFLUENZA DIAGNOSTICS MARKET 69
FIGURE 23 REVENUE SHIFT FOR THE INFLUENZA DIAGNOSTICS MARKET 69
6 INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT 70
6.1 INTRODUCTION 71
TABLE 5 INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 71
6.2 TEST KITS & REAGENTS 71
6.2.1 REPEAT PURCHASE OF TEST KITS & REAGENTS TO DRIVE MARKET GROWTH IN THE COMING YEARS 71
FIGURE 24 INSIGHTS FROM INDUSTRY EXPERTS ON TEST KITS & REAGENTS 72
TABLE 6 INFLUENZA DIAGNOSTICS MARKET FOR TEST KITS & REAGENTS, BY REGION, 2019–2026 (USD MILLION) 72
6.3 INSTRUMENTS 73
6.3.1 INCREASING NEED FOR FASTER & MORE ACCURATE TEST RESULTS TO PROPEL MARKET GROWTH 73
TABLE 7 KEY INSTRUMENTS IN THE INFLUENZA DIAGNOSTICS MARKET 74
TABLE 8 INFLUENZA DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION,
2019–2026 (USD MILLION) 74
6.4 OTHER PRODUCTS 74
TABLE 9 INFLUENZA DIAGNOSTICS MARKET FOR OTHER PRODUCTS, BY REGION, 2019–2026 (USD MILLION) 75
7 INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE 76
7.1 INTRODUCTION 77
TABLE 10 INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE,
2019–2026 (USD MILLION) 77
7.2 MOLECULAR DIAGNOSTIC TESTS 77
TABLE 11 MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 78
TABLE 12 MOLECULAR DIAGNOSTIC TESTS MARKET, BY REGION,
2019–2026 (USD MILLION) 78
7.2.1 POLYMERASE CHAIN REACTION TESTS 78
7.2.1.1 Ability of PCR tests to distinguish between influenza A and B viruses is driving its adoption in clinical settings 78
TABLE 13 POLYMERASE CHAIN REACTION TESTS MARKET, BY REGION,
2019–2026 (USD MILLION) 79
7.2.2 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS 79
TABLE 14 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 80
TABLE 15 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET, BY REGION, 2019–2026 (USD MILLION) 80
7.2.2.1 Transcription-mediated amplification-based assays 80
7.2.2.1.1 Wide application range in pathogen detection to drive the market growth 80
TABLE 16 TRANSCRIPTION-MEDIATED AMPLIFICATION-BASED ASSAYS MARKET,
BY REGION, 2019–2026 (USD MILLION) 81
7.2.2.2 Loop-mediated isothermal amplification-based assays 81
7.2.2.2.1 Rapidity, stability, and sensitivity have driven the use of loop-mediated isothermal amplification-based assays 81
TABLE 17 LOOP-MEDIATED ISOTHERMAL AMPLIFICATION-BASED ASSAYS MARKET,
BY REGION, 2019–2026 (USD MILLION) 81
7.2.2.3 Nucleic acid sequence-based amplification assays 82
7.2.2.3.1 Nucleic acid sequence-based amplification assays are preferred in hospitals and clinical settings as they reduce the need for additional reverse transcription steps 82
TABLE 18 NUCLEIC ACID SEQUENCE-BASED AMPLIFICATION ASSAYS MARKET,
BY REGION, 2019–2026 (USD MILLION) 82
7.2.2.4 Other isothermal nucleic acid amplification tests 82
TABLE 19 OTHER ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET,
BY REGION, 2019–2026 (USD MILLION) 83
7.2.3 OTHER MOLECULAR DIAGNOSTIC TESTS 83
TABLE 20 OTHER MOLECULAR DIAGNOSTIC TESTS MARKET, BY REGION,
2019–2026 (USD MILLION) 83
7.3 TRADITIONAL DIAGNOSTIC TESTS 84
TABLE 21 TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 84
TABLE 22 TRADITIONAL DIAGNOSTIC TESTS MARKET, BY REGION,
2019–2026 (USD MILLION) 84
7.3.1 RAPID INFLUENZA DIAGNOSTIC TESTS 84
7.3.1.1 Rapid influenza diagnostic tests are widely used due to their ease of use and rapid interpretability of results 84
TABLE 23 RAPID INFLUENZA DIAGNOSTIC TESTS MARKET, BY REGION,
2019–2026 (USD MILLION) 85
7.3.2 VIRAL CULTURE TESTS 85
7.3.2.1 Wide use of viral cultures as confirmatory tests to ensure the results of RIDTs to drive market growth 85
TABLE 24 VIRAL CULTURE TESTS MARKET, BY REGION, 2019–2026 (USD MILLION) 86
7.3.3 DIRECT FLUORESCENT ANTIBODY TESTS 86
7.3.3.1 Adoption of DFA tests is increasing due to their higher sensitivity compared to RIDTs 86
TABLE 25 DIRECT FLUORESCENT ANTIBODY TESTS MARKET, BY REGION,
2019–2026 (USD MILLION) 87
7.3.4 SEROLOGICAL TESTS 87
7.3.4.1 Development of lab-on-chip-based multiplex assays to support market growth 87
TABLE 26 SEROLOGICAL TESTS MARKET, BY REGION, 2019–2026 (USD MILLION) 88

8 INFLUENZA DIAGNOSTICS MARKET, BY END USER 89
8.1 INTRODUCTION 90
TABLE 27 INFLUENZA DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 90
8.2 DIAGNOSTIC LABORATORIES 90
8.2.1 LARGE NUMBER OF INFLUENZA DIAGNOSTIC TESTS PERFORMED IN DIAGNOSTIC LABORATORIES TO DRIVE MARKET GROWTH 90
TABLE 28 INFLUENZA DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES,
BY REGION, 2019–2026 (USD MILLION) 91
8.3 HOSPITALS & CLINICS 91
8.3.1 GROWING GLOBAL NUMBER OF HOSPITALS DUE TO INCREASING INFECTIOUS DISEASE INCIDENCE TO DRIVE MARKET GROWTH 91
TABLE 29 INFLUENZA DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS,
BY REGION, 2019–2026 (USD MILLION) 92
8.4 OTHER END USERS 92
TABLE 30 INFLUENZA DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2019–2026 (USD MILLION) 92
9 INFLUENZA DIAGNOSTICS MARKET, BY REGION 93
9.1 INTRODUCTION 94
TABLE 31 INFLUENZA DIAGNOSTICS MARKET, BY REGION, 2019–2026 (USD MILLION) 94
TABLE 32 INFLUENZA DIAGNOSTICS MARKET, BY REGION,
2019–2026 (MILLION TESTS) 94
9.2 NORTH AMERICA 95
FIGURE 25 NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET SNAPSHOT 95
TABLE 33 NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 96
TABLE 34 NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 96
TABLE 35 NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE,
2019–2026 (USD MILLION) 96
TABLE 36 NORTH AMERICA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 97
TABLE 37 NORTH AMERICA: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION) 97
TABLE 38 NORTH AMERICA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION) 97
TABLE 39 NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 98
9.2.1 US 98
9.2.1.1 Technological advancements in influenza diagnostics to favor market growth in the US 98
TABLE 40 US: PRODUCT APPROVALS IN THE INFLUENZA DIAGNOSTICS MARKET 98
TABLE 41 US: INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 99
TABLE 42 US: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE,
2019–2026 (USD MILLION) 99
TABLE 43 US: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 100
TABLE 44 US: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION) 100
TABLE 45 US: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 100
TABLE 46 US: INFLUENZA DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 101
9.2.2 CANADA 101
9.2.2.1 Government initiatives for developing diagnostic techniques to support market growth in Canada 101
TABLE 47 CANADA: INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 102
TABLE 48 CANADA: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE,
2019–2026 (USD MILLION) 102
TABLE 49 CANADA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 102
TABLE 50 CANADA: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET,
BY TYPE, 2019–2026 (USD MILLION) 103
TABLE 51 CANADA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 103
TABLE 52 CANADA: INFLUENZA DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 103
9.3 EUROPE 104
TABLE 53 EUROPE: INFLUENZA DIAGNOSTICS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 104
TABLE 54 EUROPE: INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 105
TABLE 55 EUROPE: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE,
2019–2026 (USD MILLION) 105
TABLE 56 EUROPE: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 105
TABLE 57 EUROPE: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET,
BY TYPE, 2019–2026 (USD MILLION) 106
TABLE 58 EUROPE: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 106
TABLE 59 EUROPE: INFLUENZA DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 106
9.3.1 GERMANY 107
9.3.1.1 Increasing demand for technologically advanced diagnostic techniques to drive market growth in Germany 107
TABLE 60 GERMANY: INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 107
TABLE 61 GERMANY: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE,
2019–2026 (USD MILLION) 107
TABLE 62 GERMANY: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 108
TABLE 63 GERMANY: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET,
BY TYPE, 2019–2026 (USD MILLION) 108
TABLE 64 GERMANY: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 108
TABLE 65 GERMANY: INFLUENZA DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 109
9.3.2 ITALY 109
9.3.2.1 Well-developed healthcare system in Italy to drive the adoption of advanced diagnostic technologies 109
TABLE 66 ITALY: INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 109
TABLE 67 ITALY: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE,
2019–2026 (USD MILLION) 110
TABLE 68 ITALY: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 110
TABLE 69 ITALY: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION) 110
TABLE 70 ITALY: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 111
TABLE 71 ITALY: INFLUENZA DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 111
9.3.3 FRANCE 111
9.3.3.1 High healthcare expenditure by the government to drive market growth in France 111
TABLE 72 FRANCE: INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 112
TABLE 73 FRANCE: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE,
2019–2026 (USD MILLION) 112
TABLE 74 FRANCE: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 112
TABLE 75 FRANCE: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET,
BY TYPE, 2019–2026 (USD MILLION) 113
TABLE 76 FRANCE: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 113
TABLE 77 FRANCE: INFLUENZA DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 113
9.3.4 SPAIN 114
9.3.4.1 Healthcare infrastructural improvements indicate favorable prospects for market growth in Spain 114
TABLE 78 SPAIN: INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 114
TABLE 79 SPAIN: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE,
2019–2026 (USD MILLION) 114
TABLE 80 SPAIN: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 115
TABLE 81 SPAIN: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET,
BY TYPE, 2019–2026 (USD MILLION) 115
TABLE 82 SPAIN: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 115
TABLE 83 SPAIN: INFLUENZA DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 116
9.3.5 UK 116
9.3.5.1 Frequent influenza outbreaks in the UK to boost the growth of the influenza diagnostics market 116
TABLE 84 UK: INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 116
TABLE 85 UK: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE,
2019–2026 (USD MILLION) 117
TABLE 86 UK: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 117
TABLE 87 UK: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION) 117
TABLE 88 UK: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 118
TABLE 89 UK: INFLUENZA DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 118
9.3.6 REST OF EUROPE 118
TABLE 90 ROE: INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 118
TABLE 91 ROE: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE,
2019–2026 (USD MILLION) 119
TABLE 92 ROE: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 119
TABLE 93 ROE: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION) 119
TABLE 94 ROE: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 120
TABLE 95 ROE: INFLUENZA DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 120
9.4 ASIA PACIFIC 120
FIGURE 26 ASIA PACIFIC: INFLUENZA DIAGNOSTICS MARKET SNAPSHOT 121
TABLE 96 ASIA PACIFIC: INFLUENZA DIAGNOSTICS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 122
TABLE 97 ASIA PACIFIC: INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 122
TABLE 98 ASIA PACIFIC: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE,
2019–2026 (USD MILLION) 122
TABLE 99 ASIA PACIFIC: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 123
TABLE 100 ASIA PACIFIC: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION) 123
TABLE 101 ASIA PACIFIC: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 123
TABLE 102 ASIA PACIFIC: INFLUENZA DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 124
9.4.1 CHINA 124
9.4.1.1 Growing investments by government agencies to drive market growth in China 124

TABLE 103 CHINA: INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 124
TABLE 104 CHINA: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE,
2019–2026 (USD MILLION) 125
TABLE 105 CHINA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 125
TABLE 106 CHINA: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET,
BY TYPE, 2019–2026 (USD MILLION) 125
TABLE 107 CHINA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 126
TABLE 108 CHINA: INFLUENZA DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 126
9.4.2 JAPAN 126
9.4.2.1 Universal healthcare reimbursement policy to drive market growth in Japan 126
TABLE 109 JAPAN: INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 127
TABLE 110 JAPAN: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE,
2019–2026 (USD MILLION) 127
TABLE 111 JAPAN: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 127
TABLE 112 JAPAN: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET,
BY TYPE, 2019–2026 (USD MILLION) 128
TABLE 113 JAPAN: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 128
TABLE 114 JAPAN: INFLUENZA DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 128
9.4.3 INDIA 129
9.4.3.1 Increase in public and private investments in the country’s healthcare system will drive market growth 129
TABLE 115 INDIA: INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 129
TABLE 116 INDIA: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE,
2019–2026 (USD MILLION) 129
TABLE 117 INDIA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 130
TABLE 118 INDIA: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION) 130
TABLE 119 INDIA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 130
TABLE 120 INDIA: INFLUENZA DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 131
9.4.4 REST OF ASIA PACIFIC 131
TABLE 121 ROAPAC: INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 131
TABLE 122 ROAPAC: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE,
2019–2026 (USD MILLION) 132
TABLE 123 ROAPAC: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 132
TABLE 124 ROAPAC: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET,
BY TYPE, 2019–2026 (USD MILLION) 132
TABLE 125 ROAPAC: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 133
TABLE 126 ROAPAC: INFLUENZA DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 133
9.5 LATIN AMERICA 133
9.5.1 RISING DISEASE PREVALENCE AND INCREASING HEALTHCARE EXPENDITURE TO DRIVE THE LATAM MARKET 133
TABLE 127 LATIN AMERICA: INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 134
TABLE 128 LATIN AMERICA: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE,
2019–2026 (USD MILLION) 134
TABLE 129 LATIN AMERICA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 134
TABLE 130 LATIN AMERICA: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION) 135
TABLE 131 LATIN AMERICA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 135
TABLE 132 LATIN AMERICA: INFLUENZA DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 135
9.6 MIDDLE EAST & AFRICA 136
9.6.1 RISING ACCESS TO ADVANCED TECHNOLOGIES AND GROWING INVESTMENTS WILL SUPPORT MARKET GROWTH 136
TABLE 133 MIDDLE EAST & AFRICA: INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 136
TABLE 134 MIDDLE EAST & AFRICA: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2019–2026 (USD MILLION) 136
TABLE 135 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION) 137
TABLE 136 MIDDLE EAST & AFRICA: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION) 137
TABLE 137 MIDDLE EAST & AFRICA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION) 137
TABLE 138 MIDDLE EAST & AFRICA: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION) 138
10 COMPETITIVE LANDSCAPE 139
10.1 OVERVIEW 139
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 139
10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN THE INFLUENZA DIAGNOSTICS MARKET 139
TABLE 139 STRATEGIES ADOPTED BY KEY INFLUENZA DIAGNOSTIC PRODUCT MANUFACTURING COMPANIES 139
10.3 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS 140
FIGURE 27 REVENUE SHARE ANALYSIS OF THE TOP PLAYERS IN THE INFLUENZA DIAGNOSTICS MARKET 140

10.4 MARKET SHARE ANALYSIS 141
FIGURE 28 INFLUENZA DIAGNOSTICS MARKET SHARE, BY KEY PLAYER (2020) 141
TABLE 140 INFLUENZA DIAGNOSTICS MARKET: DEGREE OF COMPETITION 142
10.5 COMPANY EVALUATION QUADRANT 143
10.5.1 STARS 143
10.5.2 EMERGING LEADERS 143
10.5.3 PERVASIVE PLAYERS 143
10.5.4 PARTICIPANTS 143
FIGURE 29 INFLUENZA DIAGNOSTICS MARKET: COMPANY
EVALUATION QUADRANT, 2020 144
10.6 COMPANY EVALUATION QUADRANT FOR STARTUPS/SMES (2020) 145
10.6.1 PROGRESSIVE COMPANIES 145
10.6.2 STARTING BLOCKS 145
10.6.3 RESPONSIVE COMPANIES 145
10.6.4 DYNAMIC COMPANIES 145
FIGURE 30 INFLUENZA DIAGNOSTICS MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2020 146
10.7 COMPETITIVE BENCHMARKING 147
FIGURE 31 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS OF THE TOP PLAYERS IN THE INFLUENZA DIAGNOSTICS MARKET 147
TABLE 141 COMPANY PRODUCT FOOTPRINT 147
TABLE 142 COMPANY REGIONAL FOOTPRINT 148
10.8 COMPETITIVE SCENARIO 148
10.8.1 PRODUCT LAUNCHES & APPROVALS 148
TABLE 143 KEY PRODUCT LAUNCHES & APPROVALS 148
10.8.2 DEALS 149
TABLE 144 KEY DEALS 149
11 COMPANY PROFILES 150
11.1 KEY PLAYERS 150
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
11.1.1 THERMO FISHER SCIENTIFIC, INC. 150
TABLE 145 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW 150
FIGURE 32 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2020) 151
11.1.2 BECTON, DICKINSON AND COMPANY 154
TABLE 146 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW 154
FIGURE 33 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2020) 155
11.1.3 F. HOFFMANN-LA ROCHE AG 157
TABLE 147 F. HOFFMANN-LA ROCHE AG: BUSINESS OVERVIEW 157
FIGURE 34 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2020) 158
11.1.4 HOLOGIC, INC. 160
TABLE 148 HOLOGIC, INC.: BUSINESS OVERVIEW 160
FIGURE 35 HOLOGIC, INC.: COMPANY SNAPSHOT (2020) 161
11.1.5 ABBOTT LABORATORIES, INC. 163
TABLE 149 ABBOTT LABORATORIES, INC.: BUSINESS OVERVIEW 163
FIGURE 36 ABBOTT LABORATORIES, INC.: COMPANY SNAPSHOT (2020) 164
11.1.6 DANAHER CORPORATION 167
TABLE 150 DANAHER CORPORATION: BUSINESS OVERVIEW 167
FIGURE 37 DANAHER CORPORATION: COMPANY SNAPSHOT (2020) 168
11.1.7 QUIDEL CORPORATION 170
TABLE 151 QUIDEL CORPORATION: BUSINESS OVERVIEW 170
FIGURE 38 QUIDEL CORPORATION: COMPANY SNAPSHOT (2020) 171
11.1.8 SIEMENS HEALTHINEERS 174
TABLE 152 SIEMENS HEALTHINEERS: BUSINESS OVERVIEW 174
FIGURE 39 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT (2020) 175
11.1.9 BIOMÉRIEUX SA 176
TABLE 153 BIOMÉRIEUX SA: BUSINESS OVERVIEW 176
FIGURE 40 BIOMÉRIEUX SA: COMPANY SNAPSHOT (2020) 177
11.1.10 MERIDIAN BIOSCIENCE 179
TABLE 154 MERIDIAN BIOSCIENCE: BUSINESS OVERVIEW 179
FIGURE 41 MERIDIAN BIOSCIENCE: COMPANY SNAPSHOT (2020) 180
11.2 OTHER PLAYERS 181
11.2.1 GENMARK DIAGNOSTICS, INC. 181
11.2.2 LUMINEX CORPORATION 181
11.2.3 TECAN TRADING AG 182
11.2.4 DIASORIN SA 182
11.2.5 ALTONA DIAGNOSTICS GMBH 183
11.2.6 SEKISUI DIAGNOSTICS 183
11.2.7 SA SCIENTIFIC, LTD. 184
11.2.8 CORIS BIOCONCEPT SPRL 184
11.2.9 ELITECH GROUP 184
11.2.10 MAST GROUP LTD. 185
11.2.11 GENOME DIAGNOSTICS PVT. LTD. 185
11.2.12 GERMAINE LABORATORIES, INC. 185
11.2.13 RESPONSE BIOMEDICAL CORP. 186
11.2.14 TAUNS LABORATORIES, INC. 186
11.2.15 3B BLACKBIO BIOTECH INDIA LTD. 186
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

12 APPENDIX 187
12.1 INSIGHTS FROM INDUSTRY EXPERTS 187
12.2 DISCUSSION GUIDE 188
12.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 190
12.4 AVAILABLE CUSTOMIZATIONS 192
12.5 RELATED REPORTS 192
12.6 AUTHOR DETAILS 193


お問合せフォーム

    ※レポートのタイトルは自動で入ります。

    お名前(必須)

    会社名(必須)

    部署名

    メールアドレス(必須)

    電話番号

    当ウェブサイトを知った経由を教えてください。

    お問合せ区分(必須)

    お問合せ内容(必須)

    株式会社SEMABIZ・ChosaReport.com プライバシーポリシー

    Eメールでのお問合せもお受けしております。
    下記アドレスへ“(at)”を“@”に変えてお送りください。通常1営業日以内にご返信いたします。
    crinquiry(at)chosareport.com